Skip Nav Destination
![]()
You do not currently have access to this content.
Pembrolizumab New Care Standard for Advanced Cervical Cancer
September 16, 2024
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone. Determining the optimal duration of pembrolizumab treatment is crucial for controlling the cost of treatment.
RSS Feeds